Serum Squamous Cell Carcinoma Antigen Level in Cirrhotic Chronic Hepatitis C Patients With and Without Hepatocellular Carcinoma

Alaa El Din Mohamed Abdo, Akram Abd El-Moneim Deghady, Essam El Din Saeed Bedewy, Walid Ismail Ellakany

Abstract


This study will be carried out on 500 personnel divided into five groups : Group A: 100 cases of hepatocellular carcinoma without interventions. Group B: same 100 cases of group A before and 3 months after successful interventions.Group C: 100 cases of established cirrhosis. Group D: 100 cases with chronic hepatitis C virus infection without established cirrhosis. Group E: 100 healthy individuals as controls.
Methods: Sera from selected patients and controls have been used for estimation of SCC-Ag using CanAg SCC EIA.
Results: high significant increase in serum SCCA level in patients with HCC (groupA and groupB) when compared to cirrhotic, chronic HCV and control groups (P < 0.001). Positive significant correlation was found between AFP and serum SCCA level .The best cut-off value to differentiate HCC patients from cirrhotic patients was 3.2 ng/ml for SCCA yielded with 80% sensitivity and 90% specificity. When combined sensitivity of both markers was calculated in our study at the best-chosen cutoff values (SCCA 3.2 ng/ml and AFP 200 ng/ml) sensitivity improved to 93%.
Conclusion: Combined SCCA and AFP can be used as in diagnosis of HCC and follow up 3 months after therapeutic intervention.


Keywords


Hepatocellular carcinoma; Squamous cell carcinoma antigen; Alfa feto protein

Full Text:

PDF

References


[1] Lok, A., Seeff, L., & Morgan, T. (2009). Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C related advanced liver disease. Gastroenterology, 136, 138-48.

[2] El-Zayadi, A., & Badran, H. (2005). Hepatocellular carcinoma in Egypt: A single center study over a decade. World J Gastroenterol, 11, 5193–8.

[3] Peng, S.Y., Chen, W., & Lai, P., et al. (2004). High alpha-fetoprotein level correlates with high stage, early recurrence and poor prognosis of hepatocellular carcinoma: Significance of hepatitis virus infection, age 53 and beta-catenin mutations. Int J Cancer, 112, 44-50.

[4] Giannelli, G., & Antonaci, S. (2011). New frontiers in biomarkers for hepatocellular carcinoma. Dig Liver Disease, 38, 854-9.

[5] Biasiolo, A., Chemello, L., & Quarta, S. (2008). Squamous cell carcinoma antigen (SCCA) detection in patients with HCV infection and rheumatoid factor seropositivity. J Viral Hepat, 15, 246-9.

[6] Issa, H., Awadallah, A., & Soliman, M. (2011). Evaluation of serum chromogranin A as a useful tumor marker for diagnosis of hepatocellular carcinoma. Journal of American Science, 7, 999-1007.

[7] Feng, W., Wang Z. B., & Meng, W. C., et al. (2004). Extracorporeal high intensity focused ultrasound ablation in the treatment of patients with large hepatocellular carcinoma. Surgical Onco, 11, 1061-69.

[8] Molinari, M., Kachuray, J., Dixonz, ., Suehiro, Y., Morioka, H., & Fordtran, B., et al. (2006). Transarterial chemoembolisation for advanced hepatocellular carcinoma: Results from a North American Cancer Centre. Clinical Oncology, 18, 684-92.

[9] Hussein, M., Ibrahim, A., & Abdella, H. (2008). Evaluation of serum squamous cell carcinoma antigen as a novel biomarker for diagnosis of hepatocellular carcinoma in Egyptian patients. Indian J Cancer, 45, 167-72.

[10] El Ezawy, H., Shebil, N., & Mounis, A. (2012). Assessment of serum SCCA and KL-6 as tumor markers and their correlation with tumor size. Journal of American science, 8, 172-9.

[11] Bin, X., Fang, G. S., Liu, S, H., Kim, T., Takahashi, S. (2008). SCCA level in peripheral blood in patients with hepatocellular carcinoma before and after TACE. J Huazhong Univ Sci Technol 28, 645-8.

[12] Trevisani, F., Daniela, B., & Gianluca, F. (2012). Serum SCCA as a predictor of hepatocellular carcinoma in patients with liver cirrhosis. Open Journal of Gastroenterology, 2, 56-61.




DOI: http://dx.doi.org/10.3968/gh.v1i1.5289

Refbacks



Copyright (c)




Share us to:   


Reminder

If you have already registered in Journal A and plan to submit article(s) to Journal B, please click the CATEGORIES, or JOURNALS A-Z on the right side of the "HOME".


We only use three mailboxes as follows to deal with issues about paper acceptance, payment and submission of electronic versions of our journals to databases:
caooc@hotmail.com; gh@cscanada.net; gh@cscanada.org

 Articles published in Gastroenterology and Hepatology are licensed under Creative Commons Attribution 4.0 (CC-BY).

 GASTROENTEROLOGY AND HEPATOLOGY Editorial office

Address: 1020 Bouvier Street, Suite 400, Quebec City, Quebec, G2K 0K9, Canada. 
Telephone: 1-514-558 6138 
Website: Http://www.cscanada.net Http://www.cscanada.org 
E-mail:gh@cscanada.net, gh@cscanada.org

Copyright © 2010 Canadian Research & Development Centre of Sciences and Cultures